A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease (DeferipronPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01539837|
Recruitment Status : Unknown
Verified October 2012 by Imperial College London.
Recruitment status was: Recruiting
First Posted : February 28, 2012
Last Update Posted : October 17, 2012
|First Submitted Date ICMJE||February 22, 2012|
|First Posted Date ICMJE||February 28, 2012|
|Last Update Posted Date||October 17, 2012|
|Study Start Date ICMJE||February 2012|
|Estimated Primary Completion Date||September 2013 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||safety and efficacy [ Time Frame: 6 months ]
To assess whether 6 month treatment with Deferiprone is well tolerated by PD patients and assess whether such treatment removes excess iron in the brain area affected in PD, the substantia nigra, as assessed by MRI.
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01539837 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Disease modification [ Time Frame: 6 months ]
Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease or other brain function e.g.psychological well being, during the course of the 6 months trial period
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease|
|Official Title ICMJE||A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease|
|Brief Summary||Parkinson's disease (PD) is a common neurodegenerative disease affecting movement. Although drug treatments for PD are available they only treat the symptoms of the disease, fail to halt neuronal loss, and are associated with long term side effects and loss of efficacy. There is a chronic need to develop neuroprotective therapies. Increased iron and oxidative stress have been heavily implicated in the neurodegenerative process in PD, hence removal of excess iron by iron chelation represents a potential drug target. Iron chelators are extensively utilised to treat peripheral iron overload disorders (e.g. thalassaemia) and recently the investigators have demonstrated iron chelators such as Deferiprone can enter the brain removing excess iron and are neuroprotective in PD animal models. Although good tolerability and efficacy to remove brain iron has also been shown in a pilot study with the iron chelators Deferiprone in young patients with Friedreich Ataxia, where iron accumulates in the dentate nucleus, no studies have been conducted in aged individuals affected by PD. Hence the aims of this study are 1) to assess whether Deferiprone is well tolerated in PD patients, 2) whether Deferiprone can remove the excess iron levels found in the brain area affected by PD, the substantia nigra, as assessed by Magnetic resonance imaging (MRI) and 3) whether Deferiprone has any direct effect on the clinical symptoms of PD. Three groups of 12 (total 36) early stage drug free PD patients will be treated with 20 or 30mg/kg/d Deferiprone or Placebo for 6 months. Over the 6 months patients will receive serial MRI scans, neurological examinations not only to assess PD symptoms but also psychological state, plus blood test to monitor for potential side effects. Positive results from this pilot will help support larger clinical trials to evaluate whether Deferiprone can slow down/halt PD.|
1.1 BACKGROUND Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects approximately 2% of the population aged over 60 years. The common clinical motor control features are tremor, bradykinesia, postural abnormality and rigidity. However, in many patients non-motor features such as cognitive decline, depression, autonomic disturbances also occur as the disease progresses. The principal pathology is the degeneration of the nigrostriatal dopaminergic system which plays a major role in movement control through the release of dopamine in the striatum. Current therapeutic approach focus on dopamine replacement strategies either through the dopamine precursor L-DOPA or the use of dopamine agonists, and/or the use of monoamine oxidase inhibitors or catecholamine transferase inhibitors which prevent the breakdown of dopamine or facilitate L-DOPA entry into the brain. However, such therapeutic approaches are associated with declining efficacy and long term complications e.g. dyskinesias. Additionally, such therapeutic approaches only treat the clinical symptoms of PD and due not protect the neurons against degeneration hence the disease continues to progress with the patient experiencing increasing disability. Hence there is a chronic need for the development of neuroprotective drugs which prevent further neuronal loss and thus prevent the progression of the disease.
1.2 RATIONALE FOR CURRENT STUDY Hypothesis: Increased iron and oxidative stress play a major role in the neurodegenerative process in PD and iron chelation therapy can be effective in removing excess iron from the brain and potentially slowing the neurodegenerative process.
Research question: Can iron chelation therapy with Deferiprone remove excess iron in the substantia nigra in PD patients without toxic side effects. What effect does Deferiprone therapy have on the severity of PD and other brain function e.g. cognition, depression etc.
Increased iron levels have been heavily implicated in the neurodegenerative process in PD. Although many of our cellular processes require iron, when in excessive amounts it can trigger the formation of toxic chemicals called free radicals, of which there is extensive evidence of their increased formation in the PD brain. Hence removal of excess iron by iron chelation (drugs which bind and detoxify iron) represents a potential drug target.
Iron chelators e.g. Deferiprone in doses around 100mg/kg/day, are extensively utilised to treat peripheral iron overload disorders such as beta thalassaemia, where the patients requires regular blood transfusions but iron accumulates in the body when the red blood cells are removed from the circulation. Iron chelation therapy in such patients is associated with minimal side effects with long term use. Recently, in animal models of brain iron overload, we have demonstrated iron chelators can enter the brain removing excess iron. Additionally, we have recently shown that iron chelation therapy protects neurons against toxins in animal models of PD.
In 2007 20 or 30mg/kg/day Deferiprone was used in a pilot clinical trial in Friedreich ataxia (FA)patients, to assess whether the drug was well tolerated, removed excess brain iron and improved the clinical symptoms of FA. FA occurs due to a gene defect leading iron accumulation in the mitochondria in the cerebellum, toxicity of which leads to ataxia or inability to control muscle movements. FA is diagnosed in young individuals (14-26 years of age) and has no clinical treatment. In this 6 months FA study Deferiprone at 20 or 30mg/kg/day was well tolerated by the patients and resulted in a reduction in brain iron, as indicated by MRI brain imaging, and led to a clinical improvement in patient symptoms. Whilst this represents the first clinical use of an iron chelator to treat a neurodegenerative disorder, the FA patients in this study were young (14-23 years old) hence we do not know how aged (average age 60years) individuals commonly affected by PD will respond to iron chelator treatment. Hence the first aim of this study is to conduct the first pilot clinical trial with an iron chelator in newly diagnosed PD patients to assess tolerability along with its ability to reduce iron content in the brain area affected in PD, the substantia nigra, as assessed by MRI.
A number of clinical trials have already been conducted in PD with potential neuroprotective drugs but their ability to slow the disease process has been controversial since these drugs have a direct effects on the symptoms of PD itself. Hence it is difficult to say whether the beneficial effects of the drugs are due the prevention of further neuronal loss thus slowing the disease or whether they improve the patient's ability to move directly. PD progresses in most patients fairly slowly, hence we don't expect to see detectable neuroprotection following 6 months Deferiprone treatment but it will allow us to assess whether Deferiprone therapy has any direct effects on PD symptoms. Hence the second aim of this study will be to examine whether iron chelation therapy has a direct effect on PD symptomology.
If this pilot study clearly demonstrates good tolerability of Deferiprone in PD patients whilst showing good removal of excess SN iron level yet having minimal direct effect on PD symptomology this data will form the basis of large funding application for a multicentre clinical trials to investigate whether long term Deferiprone treatment can slow/halt the progression of PD.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 2|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Condition ICMJE||Parkinson's Disease|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Unknown status|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date||December 2013|
|Estimated Primary Completion Date||September 2013 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||50 Years to 75 Years (Adult, Older Adult)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United Kingdom|
|Removed Location Countries|
|NCT Number ICMJE||NCT01539837|
|Other Study ID Numbers ICMJE||ICL-11/SC/0101
2011-001148-31 ( EudraCT Number )
11/SC/0101 ( Other Identifier: Research Ethics Committee )
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Imperial College London|
|Study Sponsor ICMJE||Imperial College London|
|Collaborators ICMJE||Not Provided|
|PRS Account||Imperial College London|
|Verification Date||October 2012|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP